ZEALAND PHARMA A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 640.5 DKK | -1.08% |
|
-0.85% | +71.89% |
Presenter SpeechRajan Sharma (Analysts)Good afternoon, everyone. Thank you for joining for the...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity.
At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Calendar
15/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
647.5
DKK
Average target price
790.9
DKK
Spread / Average Target
+22.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +71.89% | 5.8B | |
| +16.42% | 122B | |
| +19.02% | 113B | |
| +2.97% | 22.66B | |
| -16.20% | 21.34B | |
| -39.57% | 16.92B | |
| -11.63% | 16.68B | |
| -16.22% | 16.61B | |
| +2.68% | 13.62B | |
| +21.16% | 11.04B |
- Stock Market
- Equities
- ZEAL Stock
- News Zealand Pharma A/S
- Transcript : Zealand Pharma A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 04